問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Others-Department of Laboratory Medicine

Division of General Internal Medicine

更新時間：2023-09-19

周文堅Chou, Wen-Chien
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

Recruiting Trial

85Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周文堅

List

155Cases

2024-07-01 - 2029-09-19

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-05-31 - 2028-05-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Pracinostat

Participate Sites
9Sites

Terminated7Sites

2023-03-01 - 2026-12-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-05-01 - 2023-10-18

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2022-03-31 - 2023-09-07

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting5Sites

Terminated2Sites

2023-01-23 - 2027-10-13

Phase I

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-10-01 - 2025-12-31

Phase I

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia

  • Condition/Disease

    Relapsed/Refractory Acute Myeloid Leukemia

  • Test Drug

    RO7283420

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2010-09-30 - 2012-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 10 11 12 13 14 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB